BioVie Inc. (BIVI)
BIVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.20
-9.09% on the day
Market cap
$10.4M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BIVI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001580149 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-14 |
| Latest annual report FORM 10-K FOR PERIOD ENDED JUNE 30, 2026 | 10-K | 2026-08-13 |
| Latest quarterly / interim FORM 10-Q FOR PERIOD ENDING MARCH 31, 2026 | 10-Q | 2026-05-11 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-14 |
| Latest proxy | DEF 14A | 2026-09-28 |
Source: SEC EDGAR submissions feed, 504 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BIVIW | BioVie Inc. Warrant | $0.2500 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BFRG | Bullfrog AI Holdings Inc. | $0.5689 | -2.55% | $10.5M |
| GDTC | CytoMed Therapeutics Limited | $0.8700 | +7.22% | $10.3M |
| LTRN | Lantern Pharma Inc. | $0.7107 | -3.57% | $10.6M |
| BLRX | BioLineRx Ltd. | $2.17 | 0.00% | $10.8M |
| PHIO | Phio Pharmaceuticals Corp. | $0.9345 | +1.36% | $10.9M |
| KPRX | Kiora Pharmaceuticals Inc. | $2.47 | -3.52% | $10.9M |
| TOVX | Theriva Biologics Inc. | $0.2157 | -1.69% | $9.9M |
| ENSC | Ensysce Biosciences Inc. | $0.5725 | +2.99% | $11.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier